Registered User Login
Asian Journal of Pharmaceutical Research
ISSN: 2231-5691(Online), 2231-5683(Print)
News & Conferences
Volume No. :
Issue No. :
ISSN Print :
ISSN Online :
Click to Login
Development and Evaluation of Telmisartan Pulsatile Drug Delivery by using Response Surface Methodology
Indrajeet S. Patil
Omkar A. Patil
Girish Chandra R. Mandake
Manoj M. Nitalikar
Indrajeet S. Patil*, Omkar A. Patil, Girish Chandra R. Mandake, Manoj M. Nitalikar
Department of Pharmaceutics, Rajarambapu College of Pharmacy, Kasegaon-415404, Dist-Sangli, Maharashtra, India.
The aim of present study was to develop, evaluate and optimize the pulsincap formulation on the principle based on the pulsatile drug delivery system using Telmisartan drug. Telmisartan is mainly used for treatment of high blood pressure, congestive heart failure, and to increase the chances of living longer after a heart attack. It is an angiotensin II receptor antagonist that is selective for the type I angiotensin receptor. Formalin treatment has been employed to modify the solubility of gelatin capsules. Quantitative test for formaline residue was carried out. FTIR study shown drug and excipient are compatible with each other. Hydrogel plug of various components are prepared and used in pulsincap formulation. The drug content of the formulated pulsincap was found to be in the range 92.65 to 101%. In vitro drug release study in pH 1.2 buffer was zero percent and capsule was intact for first 2 hrs. F8 formulation batch was selected as best formulation as F8 batch released maximum drug in pH 7.4 phosphate buffer than other formulation batches. In the present work an attempt has been made to develop, evaluate and optimize a time or site specific pulsatile drug delivery system of drug Telmisartan.
Pulsatile, Pulsincap, Telmisartan, Hypertension, Response surface methodology.
Indrajeet S. Patil, Omkar A. Patil, Girish Chandra R. Mandake, Manoj M. Nitalikar. Development and Evaluation of Telmisartan Pulsatile Drug Delivery by using Response Surface Methodology. Asian J. Pharm. Res. 2018; 8(4): 205-214.
Visitor's No. :